Next Article in Journal
Design, Synthesis, and In Vitro Activity of Pyrazine Compounds
Next Article in Special Issue
Investigation of Anti-Inflammatory Potential of N-Arylcinnamamide Derivatives
Previous Article in Journal
Stacks of Azobenzene Stars: Self-Assembly Scenario and Stabilising Forces Quantified in Computer Modelling
Previous Article in Special Issue
A Prospective Repurposing of Dantrolene as a Multitarget Agent for Alzheimer’s Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 23
10.3390/molecules24234388
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Design, Synthesis, and Structural Characterization of Novel Diazaphenothiazines with 1,2,3-Triazole Substituents as Promising Antiproliferative Agents

by
Beata Morak-Młodawska
1,*,
Krystian Pluta
1,
Małgorzata Latocha
2,
Małgorzata Jeleń
1 and
Dariusz Kuśmierz
2
1
Department of Organic Chemistry, Faculty of Pharmaceutical Sciences, The Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland
2
Department of Cell Biology, Faculty of Pharmaceutical Sciences, The Medical University of Silesia, Jedności 8, 41-200 Sosnowiec, Poland
*
Author to whom correspondence should be addressed.
Molecules 2019, 24(23), 4388; https://doi.org/10.3390/molecules24234388
Submission received: 28 October 2019 / Revised: 19 November 2019 / Accepted: 27 November 2019 / Published: 30 November 2019
(This article belongs to the Special Issue Facing Novel Challenges in Drug Discovery)
Browse Figures
Versions Notes

Abstract

:
A series of novel 1,2,3-triazole-diazphenothiazine hybrids was designed, synthesized, and evaluated for anticancer activity against four selected human tumor cell lines (SNB-19, Caco-2, A549, and MDA-MB231). The majority of the synthesized compounds exhibited significant potent activity against the investigated cell lines. Among them, compounds 1d and 4c showed excellent broad spectrum anticancer activity, with IC50 values ranging from 0.25 to 4.66 μM and 0.25 to 6.25 μM, respectively. The most promising compound 1d, possessing low cytotoxicity against normal human fibroblasts NHFF, was used for gene expression analysis using reverse transcription–quantitative real-time PCR (RT–qPCR). The expression of H3, TP53, CDKN1A, BCL-2, and BAX genes revealed that these compounds inhibited the proliferation in all cells (H3) and activated mitochondrial events of apoptosis (BAX/BCL-2).

Graphical Abstract

1. Introduction

The phenothiazines were the first synthetic agents to be used successfully in psychiatry as neuroleptics. The properties of this group of heterocyclic compounds was discovered in the 1950s and provoked revolutions in contemporary medicine [1]. Currently, they are also well-known clinically as substances with antibacterial, antiviral, anti-inflammatory, and anti-tuberculosis properties. There have also been numerous reports on the antitumor activity of these drugs [2,3,4,5,6]. Neuroleptic phenothiazines became the foundation for numerous studies on modified phenothiazine systems that show a wide spectrum of biological activities, including: anticancer, antibacterial, antifungal, antiviral, and antiparasitic. This rich scientific material is the subject of numerous publications that can be found in the world literature every year [7,8,9,10,11,12,13,14,15,16].
The replacement of two benzene rings with the pyridine rings leads to dipyridothiazines. These diazaphenothiazines were found to be an excellent scaffold for novel anticancer agents with high safety profile. We synthesized dipyridothiazines of the 1,6-, 1,8-, 2,7-, and 3,6-diazaphenothiazine structures with varied alkyl, aryl, heteroaryl, dialkylaminoalkyl, amidoalkyl, sulfonamidoalkyl, and dialkylaminoalkynyl substituents at the thiazine nitrogen atom. Some selected compounds showed very promising anticancer, immunosuppressant, and antioxidant activities, and low toxicity [17,18,19,20,21,22,23,24,25].
The 1,2,3-triazoles, due to their unique chemical and structural properties, have received much attention over the past decades, and have been well-recognized for their broad range of pharmacological properties. This heterocycle has been well exploited for the generation of many medicinal scaffords exhibiting anti-HIV, anticancer, antimicrobial, and antidepressant activities [26,27,28].
Several triazoles (e.g., cefatrizine, tazobactum) have been used in medicine as β-lactam antibiotics [29]. Additionally 1,2,3-triazoles can form hydrogen bonds, which play important roles for bioavailability and solubility [30]. The triazole ring is the biological linker and exhibits bioisosteric effects on various heteroaromatic and aromatic rings [31,32,33].
The association of the potency of dipyridothiazine and 1,2,3-triazole pharmacophores under the same molecular frame was the target of our on-going idea for rational design of new biologically active compounds. The bioactive dipyridothiazines (1,6-, 1,8-, 2,7-, and 3,6-diazaphenothiazine 1-4) were combined with the 1,2,3-triazole system, using 1,3-dipolar cycloaddition reaction between 2-propynyl derivatives of dipyridothiazines (1–4)a and some selected organic azides.
For the triazole hybrids, the anticancer action on the selected cancer cell lines: glioblastoma SNB-19, colorectal carcinoma Caco-2, lung cancer A549, and breast cancer MDA-MB231 were investigated. The cytotoxicity was determined towards normal human fibroblasts NHDF. In order to understand the mechanism of action and the effects on cancer biology, the expression of H3, TP53, CDKN1A, BCL-2 and BAX genes was detected for the most active compound by the RT-qPCR method.

2. Results

2.1. Chemistry

The synthetic strategy applied for the preparation of the new triazole hybrids of diazphenothiazines was founded on selection of dipyridothiazines 1–4 as the building block laid open for assembling the 1,2,3-triazole ring, as presented in Scheme 1.
The starting materials: 10H-1,6-, 1,8-, 2,7-, and 3,6-diazaphenothiazines 1–4, were transformed with 2-propynyl bromide into the propynyl derivatives (1–4)a according to the described synthesis [20,21,22,23], and further using “click chemistry”-1,3-dipolar cycloadditon (with selected azides, in toluene, in the presence of CuI as a catalyst) into substituted triazole derivatives of diazaphenothiazines (1–4)b–f in good yields (67–82%).
Bearing in mind the fact of significant biological activities of triazole systems with various benzylic and phenyl substituents [34,35,36], the following selected azides (benzyl azide, p-fluorobenzyl azide, p-chlorobenzyl azide, p-cyanobenzyl azide, and phenylthiometyl azide) were selected for the 1,3-dipolar cycloaddition.
The identification of the product structure was based on 1H, 13C NMR spectra, 2D NMR experiments: COSY and ROESY, and mass spectrometry HRMS.
The crude products of the reactions were separated by column chromatography to obtain pure final derivatives (1–4)b–f with good yields.
On the basis of previous studies, the reaction of 2-propynyl derivatives with organic azides can led to 1,4- and/or 1,5-regioisomers [26,28]. Bearing in mind the literature, using a CuI catalyst, a 1,4 regioisomer is obtained selectively [28,34]. Nevertheless, the structure of the products received had to be unambiguously confirmed. For this reason, the 2D NMR ROESY experiment of compound 1b was carried out (Figure 1, Table 1, Supplementary Material). For triazole hybrid 1b, protons of the benzylic group (CH2NTr where Tr—triazole ring) intercorrelated with aromatic proton of the 1,2,3-triazole ring and orto-protons of the benzene ring. However, if a substitution product of 1,5-regioisomer 1B was formed in the reaction, intercorrelation between the CH2 group at the thiazine nitrogen atom (CH2NTh where Th—thiazine ring) with the CH2 group at the triazole ring (CH2NTr) would be expected but was not observed.
This we consider to be proof of the presence of 1,4-disubstituted 1,2,3-triazole ring. The full correlation between the neighbouring protones showed COSY spectra (Table 1, Supplementary Material).

2.2. Anticancer Activity

Encouraged by our previous promising results in the field of antiproliferative activity of dipyridothiazines [17,18,19,20,21,22,23,24,25] as well as by the good anticancer activity of the 1,2,3-triazoles [26,27,28,29,30,31,32,33], we decided to combine the biological potentials of dipyridothiazines and triazole moieties, hoping to obtain compounds with better activity. The antiproliferative activity of all 20 new 10-substituted 1,2,3-triazole derivatives of dipyridothiazines was tested in vitro against cancer cell lines: glioblastoma SNB-19, colorectal carcinoma Caco-2, lung cancer A549, and breast cancer MDA-MB231 using the WST-1 assay. Normal human fibroblasts NHDF were used as a control. Cisplatin was used as a positive control to induce cell death. The results of the cytotoxicity studies were summarized in Table 2.
The most active derivative in relation to all tumor groups was compound 1d, which structure contained the p-chlorobenzyl substituent (IC50 = 0.25–4.66 μM). This compound also showed relatively low cytotoxicity in relation to normal fibroblasts NHDF due to the vacancy of the examined controls. This compound showed higher activity compared to cisplatin (IC50 = 0.60–10.53 μM). In the 1,6-diazaphenothiazine group, derivative 1c with the p-fluorobenzyl substituent was also characterized by high anticancer activity in relation to SNB-19 and MDA-MB231 cell lines (IC50 = 5.72–7.82 μM). 1,8-Diazaphenothiazine 2d (with the p-chlorobenzyl substituent in the 1,2,3-tiazole system) showed high cytotoxic activity in relation to lung cancer cell lines A-549 (IC50 = 1.82 μM). This compound was also active against Caco-2 (IC50 = 11.42 μM) and MDA-MB231 (IC50 = 4.71 μM) cell lines. In the group of 1,8-diazaphenothiazines derivative 2e with the p-cyanobenzyl substituent stood out. The compound showed significant activity against glioblastoma SNB-19 (IC50 = 10.62 μM) and breast cancer MDA-MB231 (IC50 = 12.04 μM). 2,7-Diazaphenothiazine 3b (with the benzyl substituent in 1,2,3-tiazole system) showed high activity against all investigated cancer cell lines (IC50 = 0.26–2.07 μM). On the other hand derivative 3f (with the phenyltiomethyl substituent in 1,2,3-triazole system) acted selectively towards A549 and MDA-MB231 cell lines. In the 3,6-diazaphenothiazine group, the highest anticancer activity was characterized by 4c derivative with the p-fluorobenzyl substituent (IC50 = 0.25–6.25 μM). This compound showed high cytotoxicity in relation to all cancer cells lines, however, it also showed high cytotoxicity in relation to normal human fibroblasts (IC50 = 2.85 μM).
Most of the tested compounds (1–4)b–f were characterized by significant antiproliferative activity in relation to the examined cancer cell lines and relatively weak cytotoxicity with respect to normal human fibroblasts. This activity was largely dependent on the location of nitrogen atoms in isomeric dipyridothiazines as well as on the substituent in the benzene ring of the 1,2,3-tiazole system.

2.3. Apoptosis Assay

10-((1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-1,6-diazaphenothiazine (1d)—the most active compound—was selected to study the mechanism of anticancer activity using RT-qPCR. In this method the gene transcriptional activities of proliferation marker (H3), cell cycle regulator (TP53 and CDKNIA), and intracellular apoptosis pathway (BCL-2 and BAX) were analyzed. The results obtained on four cancer cell lines are collected in Table 3. It has been known that the growth, metabolism, and eventual death of the cells in the body are controlled by hundreds of genes working together [35,36,37]. The gene encoding histone H3 plays a crucial role in regulation of the expression of the genetic information included in the DNA. Compound 1d strongly changed the mRNA copy number of the histone H3 gene in all cancer lines which has an influence on the modification of the chromatin structure in the cells.
It is well known, that cellular stresses such as the DNA damage and oncogene activation can change the expression of the TP53 gene encoding the p53 protein which is called the guardian of the genome of the cell. The p53 protein influences cell cycle arrest by changing the expression of CDKN1A gene encoding the p21 protein. The essential function of the p21 protein is to arrest cell cycle progression by inhibiting the activity of cyclin-dependent kinases [37,38,39].
Compound 1d significantly interfered with the amount of mRNA copies of TP53 in all investigated cancer lines. There was also a strong decline of CDKN1A copies in all cancer cells what suggests the possibility of participation in cell cycle arrest.
In biochemical processes of cells, the p53 protein determines the standard balance between the expression of the proapoptotic BAX gene and the antiapoptotic BCL-2 gene. The balance between these proteins determines whether the cell is undergoing apoptosis or interrupting the process. It is believed that the main mechanism of action of the BCL-2 family of proteins regulates the release of cytochrome c from mitochondria by changing the mitochondrial membrane permeability [40,41].
Compound 1d remarkably reduced the expression of BCL-2 in SNB-19, A549 and MDA-MB231 cancer lines, but there was a slight increase in Caco-2 cell line. On the other hand, a decrease of the expression of BAX was observed in all investigated cancer cell lines.
Analysis of the gene expression ratio BCL-2/BAX in MDA-MB231 cell showed activation of the mitochondrial apoptosis as the internal pathway of cell death. Transcriptional activity of these genes in the SNB-19, Caco-2, and A549 cells suggests a different way of cell death, possibly associated with the external pathway of apoptosis. The presented results indicate the possibility of a two-way mechanism of apoptosis caused by the hybrid of diazaphenothiazine with the 1,2,3-triazole system. However, further research is required to fully confirm this hypothesis.

3. Materials and Methods

3.1. Chemistry

The standard NMR spectra were recorded on Bruker Avance spectrometers (1H at 600 MHz, 13C at 150 MHz) in CDCl3. Two-dimensional COSY and ROESY, spectra of selected compounds were recorded on a Bruker Avance spectrometer at 600 MHz. The HRMS spectra (EI—electro impact ionisation) were run on a Brucker Impact II. The thin layer chromatography was performed on aluminium oxide 60 F254 neutral (type E) (Merck 1.05581) with CHCl3-EtOH (10:1 v/v) as eluent.
10H-1,6-diazaphenothiazine (1), 10H-1,8-diazaphenothiazine (2), 10H-2,7-diazaphenothiazine (3) and 10H-3,6-diazaphenothiazine (4) were obtained and were transformed into 10-propynyl derivatives (1–4)a according to previously described methods [18,20,21,22,23].
General Procedure for Synthesis of Compounds (1–4)b. To a solution of 10-propynyl diazaphenothiazine (1–4)a (0.120 mg, 0.5 mmol) and copper iodide (I) (catalytic amount) in dry toluene (5 mL), a corresponding organic azide (0.510 mmol) was added. The reaction mixture was stirred and heated at 70 °C for 48 h. Then the solvent mixture was distilled under reduced pressure. The dry residue was dissolved in CHCl3 and purified by column chromatography (aluminum oxide 90 active neutral, Merck 1.01077.2000, CHCl3 as eluent) to give pure triazole derivatives 1b–4f:
10-[(1-Benzyl-1H-1,2,3-triazol-4-yl)-methyl]-1,6-diazaphenothiazine (1b). (136 mg, 76%) brown oil. 1H NMR (CDCl3) δ: 5.22 (s, 2H, CH2NTh), 5.49 (s, 2H, CH2NTr), 6.76 (dd, J = 7.2 Hz, J = 4.8 Hz 1H, H3), 6.93 (dd, J = 7.2 Hz, J = 4.8 Hz, 1H, H8), 7.23 (m, 3H, 2HPh, 1H4), 7.35 (m, 3H, 3HPh), 7.46 (d, J = 7.2 Hz, 1H, H9), 7.61 (s, 1H, HTr), 7.92 (m, 2H, H7 + H2). 13C NMR: 41.94, 54.13, 116.53, 118.39, 121.57, 122.21, 124.06, 127.87, 128.68, 129.07, 134.46, 134.65, 138.52, 142.69, 143.89, 144.82, 144.88, 152.12. HRMS (EI) m/z for: [C20H16N6S + H] calc. 373.1235 Found: 373.1225
10-[(1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-1,6-diazaphenothiazine (1c). (140 mg, 74%) yellow oil. 1H NMR (CDCl3) δ: 5.22 (s, 2H, CH2NTh), 5.46 (s, 2H, CH2NTr), 6.77 (m, 1H, H3), 6.93 (m, 1H, H8), 7.05 (m, 2H, 2HPh), 7.23 (m, 3H, 2HPh, 1H4), 7.45 (m, 1H, 1H9), 7.59 (s, 1H, HTr), 7.94 (m, 2H, H7 + H2). 13C NMR: 41.94, 53.40, 115.73, 116.01, 116.53, 118.40, 121.49, 122.17, 123.91, 127.78, 129.83, 130.00, 130.05, 134.46, 138.47, 142.79, 143.93, 144.79, 145.03, 152.12. HRMS (EI) m/z for: [C20H15FN6S + H] calc. 391.1141 Found: 391.1145.
10-[(1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-1,6-diazaphenothiazine (1d). (139 mg, 70%). brown oil. 1H NMR (CDCl3) δ: 5.21 (s, 2H, CH2NTh), 5,46 (s, 2H, CH2NTr), 6.77 (m, 1H, H3), 6.92 (m, 1H, H8), 7.18 (m, 2H, 2HPh), 7.23 (m, 1H, H4), 7.32 (m, 2H, 2HPh), 7.44 (m, 1H, H9), 7.61 (s, 1H, 1HTr), 7.94 (m, 2H, H7 + H2). 13C NMR: 41.91, 54.40, 116.61, 118.43, 121.46, 122.19, 124.02, 129.25, 129.28, 133.13, 134.47, 134.72, 138.46, 142.80, 143.92, 144.82, 145.10, 152.09. HRMS (EI) m/z for: [C20H15ClN6S + H] calc. 407.0846 Found: 407.0836
10-[(1-(4-Cyanobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-1,6-diazaphenothiazine (1e). (130 mg, 67%) brown oil. 1H NMR (CDCl3) δ: 5.22 (s, 2H, CH2NTh), 5.55 (s, 2H, CH2NTr), 6.76 (m, 1H, H3), 6.91 (m, 1H, H8), 7.21 (m, 1H, H4), 7.28 (m, 2H, 2HPh), 7.41 (m, 1H, H9), 7.63 (m, 2H, 2HPh), 7.68 (s, 1H, HTr), 7.93 (m, 2H, H7 + H2). 13C NMR: 41.85, 53.36, 112.63, 116.60, 118.41, 120.29, 121.37, 122.18, 124.43, 128.29, 129.07, 132.84, 134.50, 138.41, 142.82, 143.92, 144.81, 145.32, 152.00. HRMS (EI) m/z for: [C21H15N7S + H] calc. 398.1189 Found: 398.1176
10-[(1-Phenylthiomethyl-1H-1,2,3-triazolo-4-ylo)methyl]-1,6-diazaphenothiazine (1f). (150 mg, 75%) brown oil. 1H NMR (CDCl3) δ: 5.18 (s, 2H, CH2NTh), 5.55 (s, 2H, CH2NTr), 6.79 (m, 1H, H3), 6.92 (m, 1H, H8), 7.22 (m, 6H, 5HPh, H9), 7.34 (m, 1H, H4), 7.49 (s, 1H, 1HTr), 7.92 (m, 2H, H7 + H2). 13C NMR: 41.77, 54.05, 116.49, 118.43, 121.38, 122.17, 123.70, 128.88, 129.36, 131.51, 132.89, 134.48, 138.43, 142.76, 143.91, 144.87, 144.91, 152.01. HRMS (EI) m/z for: [C20H16N6S2 + H] calc. 405.0956 Found: 405.0957
10-[(1-Benzyl-1H-1,2,3-triazol-4-yl)-methyl]-1,8-diazaphenothiazine (2b). (135 mg, 75%) brown oil. 1H NMR (CDCl3) δ: 5.31 (s, 2H, CH2NTh), 5.50 (s, 2H, CH2NTr), 6.78 (m, 1H, H3), 6.93 (m, 1H, H6), 7.19 (m, 1H, H4), 7.20 (m, 2H, HPh), 7.35 (m, 3H, HPh), 7.51 (s, 1H, HTr), 7.96 (m, 1H, H2), 8.04 (m, 1H, H7), 8.29 (m, 1H, H9). 13C NMR: 41.76, 54.13, 114.45, 118.80, 120.76, 123.35, 126.57, 127.90, 128.65, 129.08, 129.22, 134.17, 134.41, 134.68, 142.40, 144.31, 145.59, 152.65. HRMS (EI) m/z for: [C20H16N6S + H] calc. 373.1235 Found 373.1235.
10-[(1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-1,8-diazaphenothiazine (2c). (142 mg, 76%) yellow oil. 1H NMR (CDCl3) δ:5.32 (s, 2H, CH2NTh), 5.46 (s, 2H, CH2NTr), 6.78 (m, 1H, H3), 6.79 (m, 1H, H6), 7.05 (m, 2H, 2HPh), 7.19 (m, 1H, H4), 7.22 (m, 2H, 2HPh), 7.48 (s, 1H, HTr), 7.96 (m, 1H, H2), 8,08 (m, 1H, H7), 8,28 (m, 1H, H9). 13C NMR: 41.83, 53.35, 114.89, 115.73, 115.87, 115.98, 118.59, 123.22, 129.73, 129.78, 130.00, 130.55, 130.57, 131.60, 134.36, 135.79, 143.81, 144.87, 145.39, 153.00. HRMS (EI) m/z for: [C20H15FN6S + H] calc. 391.1141 Found: 391.1143.
10-[(1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-1,8-diazaphenothiazine (2d). 140 mg, 71%). brown oil. 1H NMR (CDCl3) δ: 5.31 (s, 2H, CH2NTh), 5.47 (s, 2H. CH2NTr), 6.81 (m, 1H, H3), 6.93 (m, 1H, H6), 7.18 (m, 2H, 2HPh), 7.21 (m, 1H, H4), 7.34 (m, 2H, 2HPh), 7.51 (s, 1H, HTr), 7.97 (m, 1H, H2), 8.04 (m, 1H, H7), 8.29 (m, 1H, H9). 13C NMR: 41.86, 53.25, 114.49, 115.72, 115.67, 115.98, 118.61, 123.20, 129.74, 129.76, 130.00, 130.59, 130.47, 131.66, 134.16, 135.69, 143.81, 144.77, 145.49, 153.02. HRMS (EI) m/z for: [C20H15ClN6S + H] calc. 407.0846 Found: 407.0835.
10-[(1-(4-Cyanobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-1,8-diazaphenothiazine (2e). (135 mg, 69%) brown oil. 1H NMR (CDCl3) δ: 5.34 (s, 2H, CH2NTh), 5.56 (s, 2H. CH2NTr), 6.80 (m, 1H, H3), 6.93 (m, 1H, H6), 7.21 (m, 1H, H4), 7.28 (m, 2H, HPh), 7.53 (s, 1H, HTr), 7.65 (m, 2H, HPh), 7.96 (m, 1H, H2), 8.34 (m, 2H, H7 +H9). 13C NMR: 41.83, 53.33, 112.64, 114.95, 118.20, 118.68, 123.67, 125.31, 128.24, 129.05, 132.31, 132.86, 134.42, 135.22, 139.91, 144.82, 145.25, 145.41, 152.95. HRMS (EI) m/z for: [C21H15N7S + H] calc. 398.1189 Found: 398.1192.
10-[(1-Phenylthiomethyl-1H-1,2,3-triazolo-4-ylo)methyl]-1,8-diazaphenothiazine (2f). (150 mg, 75%) brown oil. 1H NMR (CDCl3) δ: 5.28 (s, 2H, CH2NTh), 5.57 (s, 2H. CH2NTr), 6.83 (m, 1H, H3), 7.22 (m, 1H, H6), 7.28 (m, 6H, 5HPh + H4), 7.52 (s, 1H, HTr), 7.96 (m, 1H, H2), 8.07 (m, 1H, H7), 8.23 (m, 1H, H9). 13C NMR: 41.69, 54.05, 114.39, 118.86, 120.80, 123.02, 128.85, 129.45, 129.53, 129.58, 131.55, 132.54, 132.79, 133.15, 133.75, 133.90, 134.45, 142.33, 144.45, 145.65, 152.54. HRMS (EI) m/z for: [C20H16N6S2 + H] calc. 405.0956 Found: 405.0974.
10-[(1-Benzyl-1H-1,2,3-triazol-4-yl)-methyl]-2,7-diazaphenothiazine (3b). (142 mg, 79%) yellow oil. 1H NMR (CDCl3) δ: 5.14 (s, 2H, CH2NTh), 5.52 (s, 2H, CH2NTr), 6.64 (m, 1H), 6.99 (m, 1H), 7.21 (m, 2H), 7,35 (m, 3H), 7.36 (s, 1H, HTr), 8.01 (m, 4H). 13C NMR: 44.49, 54.40, 109.72, 118.39, 121.95, 126.43, 126.98, 127.58, 128.92, 129.22, 129.33, 133.51, 134.23, 134.41, 141.09, 142.95, 144.83, 146.41. 149.45, 149.87. HRMS (EI) m/z for: [C20H16N6S + H] calc. 373.1235 Found373.1241.
10-[(1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-2,7-diazaphenothiazine (3c). (155 mg, 78%) beige oil. 1H NMR (CDCl3) δ: 5.13 (s, 2H, CH2NTh), 5.47 (s, 2H, CH2NTr), 6.61 (d, J = 5.4 Hz, 1H), 6.96 (d, J = 5.4 Hz, 1H), 7.02 (m, 2H), 7.19 (m, 2H); 7.37 (s, 1H, HTr), 7.94 (s, 1H), 8.03 (s, 1H), 8.07 (d, J = 5.4 Hz, 1H), 8.12 (d, J = 5.4 Hz, 1H). 13C NMR: 44.38, 53.63, 109.61, 116.16, 116.30, 121.57, 121.95, 121.86, 129.77, 129.83, 130.08, 130.10, 133.55, 135.40, 138.02, 138.09, 143.09, 144.83, 146.56. 149.57, 149.79. HRMS (EI) m/z for: [C20H15FN6S + H] calc. 391.1141 Found: 391.1140.
10-[(1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-2,7-diazaphenothiazine (3d). (154 mg, 82%) beige oil. 1H NMR (CDCl3) δ: 5.13 (s, 2H, CH2NTh); 5.49 (s, 2H, CH2NTr), 6.62 (m, 1H), 6.97 (m, 1H), 7.17 (m, 2H), 7.35 (m, 2H), 7,39 (s, 1H, HTr), 8,14 (m, 4H). 13C NMR: 44.49, 53.69, 109.73, 117.39, 121.57, 121.91, 129.26, 129.46, 132.64, 133.60, 135.05, 135.32, 138.09, 142.98, 144.90, 145.88, 149.01, 150.19. HRMS (EI) m/z for: [C20H15ClN6S + H] calc. 407.0846 Found: 407.0855.
10-[(1-(4-Cyanobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-2,7-diazaphenothiazine (3e). (138 mg, 71%) brown oil. 1H NMR (CDCl3) δ: 5.11 (s, 2H, CH2NTh), 5.59 (s, 2H, CH2NTr); 6.66 (m, 1H), 6.97 (m, 1H), 7.31 (m, 2H), 7.46 (s, 1H, HTr), 8.04 (m, 1H), 8.17 (m, 3H). 13C NMR: 44.27, 53.64, 113.03, 118.39, 120.57, 121.37, 122.11, 122.30, 122.41, 132.87, 133.00, 137.60, 139.32, 143.33, 143.46, 144.12, 145.75, 146.20, 148.55, 149.19, 152.12. HRMS (EI) m/z for: [C21H15N7S + H] calc. 398.1189 Found: 398.1187.
10-[(1-Phenylthiomethyl-1H-1,2,3-triazolo-4-ylo)methyl]-2,7-diazaphenothiazine (3f). (155 mg, 79%) brown oil. 1H NMR (CDCl3) δ: 5.12 (s, 2H, CH2NTh), 5.59 (s, 2H, CH2NTr), 6.59 (m, 1H), 7.04 (m, 1H), 7.24 (m, 2H), 7.29 (m. 3H), 7.35 (s, 1H, HTr), 8.18 (m, 4H). 13C NMR: 44.36, 54.34, 109.81, 118.37, 121.63, 126.43, 126.98, 127.58, 128.54, 129.22, 129.33, 133.51, 134.23, 134.41, 135.31, 142.85, 144.90, 146.13. 149.13, 149.89. HRMS (EI) m/z for: [C20H16N6S2 + H] calc. 405.0956 Found: 405.0963.
10-[(1-Benzyl-1H-1,2,3-triazol-4-yl)-methyl]-3,6-diazaphenothiazine (4b). (144 mg, 80%) yellow oil. 1H NMR (CDCl3) δ: 5.07 (s, 2H, CH2NTh), 5.27 (s, 2H, CH2NTr), 6.62 (m, 1H), 6.94 (m, 1H), 6.98 (m, 1H), 7.21 (m, 2H, HPh), 7.36 (m, 3H, HPh), 7.37 (s, 1H, HTr), 8.03 (m, 1H), 8.19 (m, 2H). 13C NMR: 44.52, 54.45, 109.31, 121.40, 122.04, 122.12, 124.97, 126.39, 128.01, 128.87, 129.34, 130.44, 134.21, 137.68, 142.95, 144.03, 145.63, 145.96, 148.34, 149.25. HRMS (EI) m/z for: [C20H16N6S + H] calc. 373.1235 Found 373.1229.
10-[(1-(4-Fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-3,6-diazaphenothiazine (4c). (154 mg, 82%) beige oil. 1H NMR (CDCl3) δ: 5.03 (s, 2H, CH2NTh), 5.47 (s, 2H, CH2NTr), 6.53 (m, 1H), 6.89 (m, 2H), 7.05 (m, 2H, HPh), 7.19 (m, 2H, HPh), 7.39 (s, 1H, HTr), 7.95 (m, 1H), 8.05 (m, 1H), 8.10 (m, 1H). 13C NMR: 44.33, 53.63, 109.09, 115.84, 116.32, 118.68, 121.66, 122.04, 129.84, 130.14, 137.79, 143.19, 143.76, 145.70, 146.81, 148.76, 148.87, 149.09. HRMS (EI) m/z for: [C20H15FN6S + H] calc. 391.1141 Found: 391.1140.
10-[(1-(4-Chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-3,6-diazaphenothiazine (4d). (150 mg, 76%) beige oil. 1H NMR (CDCl3) δ: 5.07 (s, 2H, CH2NTh), 5.48 (s, 2H, CH2NTr), 6.59 (m, 1H), 6.93 (m, 2H, HPh), 7.16 (m, 2H, HPh), 7.39 (s, 1H, HTr), 7.95 (m, 1H), 8.02 (m,1H), 8.10 (m, 1H). 13C NMR: 44.21, 53.64, 109.19, 115.64, 116.22, 118.68, 121.86, 122.14, 129.94, 130.24, 137.89, 143.39, 143.96, 145.80, 146.85, 148.66, 148.97, 149.19. HRMS (EI) m/z for: [C20H15ClN6S + H] calc. 407.0846 Found: 407.0837.
10-[(1-(4-Cyanobenzyl)-1H-1,2,3-triazol-4-yl)methyl]-3,6-diazaphenothiazine (4e). (139 mg, 72%) brown oil. 1H NMR (CDCl3) δ: 5.11 (s, 2H, CH2NTh), 5.59 (s, 2H, CH2NTr), 6.63 (m, 1H), 6.96 (m, 2H), 7.32 (m, 2H, HPh), 7.48 (s, 1H, HTr), 7.67 (m, 2H, HPh), 8.05 (m, 1H), 8.14 (m, 2H). 13C NMR: 44.27, 53.65, 109.21, 113.05, 117.99, 121.36, 122.07, 122.11, 127.88, 128.01, 128.52, 132.83, 132.87, 133.02, 135.58, 137.60, 139.30, 143.47, 144.12, 148.34, 149.25. HRMS (EI) m/z for: [C21H15N7S + H] calc. 398.1189 Found: 398.1184.
10-[(1-Phenylthiomethyl-1H-1,2,3-triazolo-4-ylo)methyl]-3,6-diazaphenothiazine (4f). (153 mg, 78%) brown oil. 1H NMR (CDCl3) δ: 5.05 (s, 2H, CH2NTh), 5.62 (s, 2H, CH2NTr), 6.55 (m, 1H), 6.93 (m, 1H), 6.97 (m, 1H), 7.24 (m, 5H), 7.33 (s, 1H, HTr), 8.07 (m, 1H), 8.15 (m, 2H). 13C NMR: 44.45, 54.26, 109.01, 121.43, 121.72, 122.21, 129.08, 129.58, 131.21, 132.52, 137.37, 142.66, 144.33, 145.01, 145.38, 147.62, 149.76. HRMS (EI) m/z for: [C20H16N6S2 + H] calc. 405.0956 Found: 405.0955.

3.2. Anticancer Effects In Vitro

3.2.1. Cell Culture

All dipyridothiazines with 1,2,3-triazole substituents (1–4)b–f were evaluated for their anticancer activity using four cultured cell lines: SNB-19 (human glioblastoma, DSMZ—German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany), Caco-2 (human colon adenocarcinoma, DSMZ—German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany), A549 (human lung carcinoma, ATCC, Manassas, VA, USA) and MDA-MB231 (human breast adenocarcinoma, ATCC, Manassas, VA, USA), and NHDF (human dermal fibroblast cell line, ATCC, Manassas, VA, USA. The cultured cells were kept at 37 °C and 5% CO2. The cells were seeded (1 × 104 cells/well/100 µL DMEM supplemented with 10% FCS and streptomycin and penicillin) using 96-well plates (Corning). The cells were counted in a hemocytometer (Burker’s chamber) using a phase contrast Olympus IX50 microscope equipped with Sony SSC-DC58 AP camera and Olympus DP10 digital camera.

3.2.2. Cell Proliferation and Viability

Antiproliferative effect of the obtained compounds on the cancer cells was determined using the cell proliferation reagent WST-1 assay (Roche Diagnostics, Mannheim, Germany). This assay is based on the viable cell’s ability to cleave the bright red-colored tetrazolium salt (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) to dark red soluble formazan by cellular enzymes. An increase in the amount of formazan dye formed correlates to the number of metabolically active cells in the culture. The formazan dye produced by metabolically active cells is quantified by a scanning ELISA reader by measuring the absorbance of the dye solution at appropriate wavelengths. The examined cells were exposed to the tested compounds for 72 h at various concentrations between 0.1 μg/mL and 100 μg/mL (prepared initially at concentration of 1 mg/mL in DMSO). The cells were incubated with WST-1 (10 μL) for 1 h and the absorbance of the samples against a background control was measured at 450 nm using a microplate reader with a reference wavelength at 600 nm. The results are expressed as means of at least two independent experiments performed in triplicate. The antiproliferative activity of the tested compound was compared to cisplatin. The IC50 values (a concentration of a compound that is required for 50% inhibition) were calculated from the dose-response relationship with respect to control.

3.2.3. The RT-qPCR Method

Genes trancriptional activity (H3, TP53, CDKN1A, BCL-2, and BAX) was evaluated by real time RT-qPCR with OPTICON TM DNA Engine (MJ Research, Watertown, MA, USA) and QuantTect® SYBR® Green RT-PCR Kit (Quiagen, Valencia, CA). Cells were exposed to compound 4 at a 0.5 µg/mL concentration for 24 h. The RNA extraction was made by using Quick-RNA™ Kit MiniPrep (ZYMO RESEARCH). Total RNA integrity was analysed in 1.2% agarose electrophoresis with added ethidium bromide. The quantity and purity of extracted total RNA were determined by using spectrophotometric analysis with HP845 (Hewlett Packard, Waldbronn, Germany) spectrophotometer. The statistical analysis was performed using the Statistica 8.0 software. All values were expressed as means ± SE.

4. Conclusions

We report here efficient synthesis of a new isomeric series of novel 1,2,3-triazole-dipyridothiazine hybrids in the 1,3-dipolar cycloadditon reactions. The structure of these new compounds was identified using advanced two-dimensional 1H and 13C NMR (COSY, ROESY) spectra. Most of the obtained derivatives of diazaphenothiazines exhibited significant anti-proliferative activities against the human glioblastoma SNB-19, colorectal carcinoma Caco-2, breast cancer MDA-MB-231 and lung cancer A549 cell lines with the IC50 values < 1 μM and were more potent than cisplatin. The most promising compound 1d was used for gene expression analysis by the RT-qPCR method. The expression of H3, TP53, CDKN1A, BCL-2, and BAX genes revealed that this compound inhibited the proliferation in all cells (H3) and activated mitochondrial events of apoptosis (BCL-2/BAX) in MDA-MB231 cancer cell line. Further in vitro and in vivo studies are required to determine the potential pharmacological use of these dipyrido-1,2,3-triazole hybrids in anticancer therapy.

Supplementary Materials

The supplementary materials are available online.

Author Contributions

B.M.-M. and K.P. developed the concept of the work. B.M.-M. carried out the synthetic work and interpreted the results. M.J. contributed to the synthesis and purification selected compounds. M.L. and D.K. carried out the biological experiments and interpreted the results. All authors have given approval to the final version of the manuscript.

Funding

This research was funded by the Medical University of Silesia in Katowice, grant KNW-1-055/K/9/O.

Acknowledgments

The work was supported by the Medical University of Silesia in Katowice (Grant KNW-1-055/K/9/O.).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mitchell, S.C. Phenothiazine: The Parent molecule. Curr. Drug Targ. 2006, 7, 1181–1189. [Google Scholar] [CrossRef] [PubMed]
  2. Amaral, L.; Viveiros, M. Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action. Antibiotics 2017, 6, 3. [Google Scholar] [CrossRef] [PubMed]
  3. Yue, H.; Huang, D.; Qin, L.; Zheng, Z.; Hua, L.; Wang, G.; Huang, J.; Huang, H. Targeting Lung Cancer Stem Cells with Antipsychological Drug Thioridazine. BioMed Res. Int. 2016, 2016, 6709828. [Google Scholar] [CrossRef] [PubMed]
  4. Mosnaim, A.D.; Ranade, V.V.; Wolf, M.E. Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents. Am. J. Ther. 2006, 13, 261–273. Available online: https://journals.lww.com/americantherapeutics/toc/2006/05000 (accessed on 12 June 2019). [CrossRef]
  5. Dasgupta, A.; Dastridara, S.G.; Shirataki, Y.; Motohashi, N. Antibacterial activity of artificial phenothiazines and isoflavones from plants. Top Heterocycl. Chem. 2008, 15, 67–132. [Google Scholar]
  6. Aaron, J.J.; Gaye Seye, M.D.; Trajkovska, S.; Motohashi, N. Bioactive Phenothiazines and Benzo[a]phenothiazines: Spectroscopic studies and biological and biomedical properties and applications. Top Heterocycl. Chem. 2009, 16, 153–231. [Google Scholar]
  7. Pluta, K.; Morak-Młodawska, B.; Jeleń, M. Synthesis and properties of diaza-, triaza- and tetraazaphenothiazines. J. Heterocycl. Chem. 2009, 46, 355–391. [Google Scholar] [CrossRef]
  8. Pluta, K.; Jeleń, M.; Morak-Młodawska, B.; Zimecki, M.; Artym, J.; Kocięba, M.; Zaczyńska, E. Azaphenothiazines a promising phenothiazine derivatives. An insight into nomenclature, synthesis, structure elucidation and biological properties. Eur. J. Med. Chem. 2017, 138, 774–806. [Google Scholar] [CrossRef]
  9. Pluta, K.; Morak-Młodawska, B.; Jeleń, M. Recent progress in biological activities of synthesized phenothiazines. Eur. J. Med. Chem. 2011, 46, 3179–3189. [Google Scholar] [CrossRef]
  10. Jaszczyszyn, A.; Gąsiorowski, K.; Świątek, P.; Malinka, W.; Cieślik-Boczula, K.; Petrus, J.; Czarnik-Matusewicz, B. Chemical structure of phenothiazines and their biological activity. Pharmacol. Rep. 2012, 64, 16–23. Available online: http://www.if-pan.krakow.pl/pjp/pdf/2012/1_16.pdf (accessed on 12 June 2019). [CrossRef]
  11. Jeleń, M.; Pluta, K.; Latocha, M.; Morak-Młodawska, B.; Suwińska, K.; Kusmierz, D. Evaluation of angularly condensed diquinothiazines as potential anticancer agents. Bioorg. Chem. 2019, 87, 810–820. [Google Scholar] [CrossRef]
  12. González-Muñoz, G.C.; Arce, M.P.; López, B.; Pérez, C.; Villarroya, M.; López, M.G.; García, A.G.; Conde, S.; Rodríguez-Franco, M.I. Old phenothiazine and dibenzothiadiazepine derivatives for tomorrow’s neuroprotective therapies against neurodegenerative diseases. Eur. J. Med. Chem. 2010, 45, 6152–6158. [Google Scholar] [CrossRef] [PubMed]
  13. Strządala, L.; Fiedorowicz, A.; Wysokińska, E.; Zioło, E.; Grudzień, M.; Jeleń, M.; Pluta, K.; Morak-Młodawska, B.; Zimecki, M.; Kałas, W. An Anti-Inflammatory Azaphenothiazine Inhibits Interferon β Expression and CXCL10 Production in KERTr Cells. Molecules 2018, 23, 2433. [Google Scholar] [CrossRef] [PubMed]
  14. Presti, M.; Bazán, P.; Strauss, M.; Báez, A.; Rivarola, H.; Paglini-Oliva, P. Trypanothione reductase inhibitors: Overview of the action of thioridazine in different stages of Chagas disease. Acta Trop. 2015, 145, 79–87. [Google Scholar] [CrossRef]
  15. Spengler, G.; Csonka, A.; Molnar, J.; Amaral, L. The anticancer activity of the old neuroleptic phenothiazine-type drug thioridazine. Anticancer Res. 2016, 36, 5701–5706. [Google Scholar] [CrossRef]
  16. Liu, N.; Jin, Z.; Zhang, J.; Jin, J. Antitumor evaluation of novel phenothiazine derivatives that inhibit migration and tubulin polymerization against gastric cancer MGC-803 cells. Investig. New Drugs 2018, 37, 188–198. [Google Scholar] [CrossRef]
  17. Pluta, K.; Jeleń, M.; Morak-Młodawska, B.; Zimecki, M.; Artym, J.; Kocięba, M. Anticancer activity of newly synthesized azaphenothiazines in NCI’s anticancer screening. Pharmacol. Rep. 2010, 62, 319–332. Available online: http://www.if-pan.krakow.pl/pjp/pdf/2010/2_319.pdf (accessed on 12 June 2019). [CrossRef]
  18. Morak-Młodawska, B.; Pluta, K.; Matralis, A.N.; Kourounakis, A.P. Antioxidant Activity of Newly Synthesized 2, 7-Diazaphenothiazines. Arch. Pharm. Int. J. Pharm. Med. Chem. 2010, 343, 268–273. [Google Scholar] [CrossRef]
  19. Zimecki, M.; Artym, J.; Kocięba, M.; Pluta, K.; Morak-Młodawska, B.; Jeleń, M. Immunosupressive activities of newly synthesized azaphenothiazines in human and mouse models. Cell. Mol. Biol. Lett. 2009, 14, 622–635. [Google Scholar] [CrossRef]
  20. Morak-Młodawska, B.; Pluta, K.; Zimecki, M.; Jeleń, M.; Artym, J.; Kocięba, M. Synthesis and selected immunological properties of 10-substituted 1, 8-diazaphenothiazines. Med. Chem. Res. 2015, 24, 1408–1418. [Google Scholar] [CrossRef]
  21. Morak-Młodawska, B.; Pluta, K.; Latocha, M.; Jeleń, M.; Kuśmierz, D. Synthesis and anticancer and lipophilic properties of 10-dialkylaminobutynyl derivatives of 1, 8- and 2, 7-diazaphenothiazines. J. Enzyme Inhib. Med. Chem. 2016, 31, 1132–1138. [Google Scholar] [CrossRef] [PubMed]
  22. Morak-Młodawska, B.; Pluta, K.; Latocha, M.; Jeleń, M. Synthesis, spectroscopic characterization, and anticancer activity of new 10-substituted 1, 6-diazaphenothiazines. Med. Chem. Res. 2016, 25, 2425–2433. [Google Scholar] [CrossRef] [PubMed]
  23. Morak-Młodawska, B.; Pluta, K.; Latocha, M.; Suwińska, K.; Jeleń, M.; Kuśmierz, D. 3, 6-Diazaphenothiazines as potential lead molecules-synthesis, characterization and anticancer activity. J. Enzyme Inhib. Med. Chem. 2016, 31, 1512–1519. [Google Scholar] [CrossRef] [PubMed]
  24. Zhang, J.; Chen, M.; Wenzhi, Z.; Okechukwu, P.N.; Morak-Młodawska, B.; Pluta, K.; Jeleń, M.; Md Akim, A.; Ang, K.-P.; Ooi, K.K. 10H-3, 6-Diazaphenothiazines Induce G2/M Phase Cell Cycle Arrest, Caspase-dependent Apoptosis and Inhibits Cell Invasion of A2780 Ovarian Carcinoma Cells through Regulation on NF-κB and [BIRC6-XIAP] Complexes. Drug Des. Dev. Ther. 2017, 11, 3045–3063. [Google Scholar] [CrossRef] [PubMed]
  25. Morak-Młodawska, B.; Pluta, K.; Latocha, M.; Jeleń, M.; Kuśmierz, D. Synthesis, anticancer activity and apoptosis induction of novel 3, 6-diazaphenothiazines. Molecules 2019, 24, 267. [Google Scholar] [CrossRef]
  26. Dheer, D.; Singh, V.; Shankar, R. Medicinal attributes of 1, 2, 3-triazoles: Current developments. Bioorg. Chem. 2017, 71, 30–54. [Google Scholar] [CrossRef]
  27. Duan, Y.C.; Ma, Y.C.; Zhang, E.; Shi, X.J.; Wang, M.M.; Ye, X.W.; Liu, H.M. Design and synthesis of novel 1, 2, 3-triazole-dithiocarbamate hybrids as potential anticancer agents. Eur. J. Med. Chem. 2013, 62, 11–19. [Google Scholar] [CrossRef]
  28. Totobennazara, J.; Burke, J.A. New click-chemistry methods for 1, 2, 3-triazoles synthesis: Recent advances and applications. Tetrahedron Lett. 2015, 56, 2853–2859. [Google Scholar] [CrossRef]
  29. Sharma, P.; Kumar, A.; Upadhyay, S.; Singh, J.; Sahu, V. A novel approach to the synthesis of 1, 2, 3-triazoles and their SAR studies. Med. Chem. Res. 2010, 19, 589–602. [Google Scholar] [CrossRef]
  30. Vatmurge, N.S.; Hazra, B.G.; Pore, V.S.; Shirazi, F.; Chavan, P.S.; Deshpande, M.V. Synthesis and antimicrobial activity of lactam-bile acid conjugates linked via triazole. Bioorg. Med. Chem. Lett. 2008, 18, 2043–2047. [Google Scholar] [CrossRef]
  31. Thirumurugan, P.; Matosiuk, D.; Jóźwiak, K. Click Chemistry for Drug Development and Diverse Chemical-Biology Application. Chem. Rev. 2013, 113, 4905–49792. [Google Scholar] [CrossRef] [PubMed]
  32. Sharma, J.; Ahmad, S.; Alam, M.S. Bioactive triazoles: A potential review. J. Chem. Pharm. Res. 2012, 4, 5157–5164. [Google Scholar]
  33. Keri, R.S.; Patil, S.A.; Budagumpi, S.; Nagaraja, B.M. Triazole: Apromising antitubercular agent. Chem. Biol. Drug Des. 2015, 86, 410–423. [Google Scholar] [CrossRef] [PubMed]
  34. McNulty, J.; Keskar, K. A Robust, Well-Defined Homogeneous Silver(I) Catalyst for MildIntramolecular Hydroamination of 2-Ethynylanilines Leading to Indoles. Eur. J. Org. Chem. 2014, 2014, 1622–1629. [Google Scholar] [CrossRef]
  35. Allen, M.A.; Andrysik, Z.; Dengler, V.L.; Mellert, H.S.; Guarnieri, A.; Freeman, J.A.; Sullivan, K.D.; Galbraith, M.D.; Luo, X.; Dowell, R.D.; et al. Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. Elife 2014, 3, 1–29. [Google Scholar] [CrossRef]
  36. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 2009, 324, 1029–1033. [Google Scholar] [CrossRef] [Green Version]
  37. Beberok, A.; Wrześniok, D.; Rok, J.; Rzepka, Z.; Respondek, M.; Buszman, E. Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. Int. J. Oncol. 2018, 52, 1727–1737. [Google Scholar] [CrossRef] [Green Version]
  38. Beberok, A.; Rzepka, Z.; Respondek, M.; Rok, J.; Sierotowicz, D.; Wrześniok, D. GSH depletion, mitochondrial membrane breakdown, caspase-3/7 activation and DNA fragmentation in U87MG glioblastoma cells: New insight into the mechanism of cytotoxicity induced by fluoroquinolones. Eur. J. Pharmacol. 2018, 835, 94–107. [Google Scholar] [CrossRef]
  39. Dutto, I.; Tillhon, M.; Cazzalini, O.; Stivala, L.A.; Prosperi, E. Biology of the cell cycle inhibitor p21 CDKN1A: Molecular, mechanisms and relevance in chemical toxicology. Arch. Toxicol. 2015, 89, 155–178. [Google Scholar] [CrossRef]
  40. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516. [Google Scholar] [CrossRef]
  41. Hemann, M.T.; Lowe, S.W. The p53-Bcl-2 connection. Cell Death Differ. 2006, 13, 1256–1259. [Google Scholar] [CrossRef] [PubMed]
Sample Availability: Samples of the compounds. 1b–4f. are available from the authors.
Molecules 24 04388 sch001 550
Scheme 1. Synthesis of 1,2,3-triazole derivatives of dipyridothiazines (1–4)b–f.
Scheme 1. Synthesis of 1,2,3-triazole derivatives of dipyridothiazines (1–4)b–f.
Molecules 24 04388 sch001
Molecules 24 04388 g001 550
Figure 1. The ROESY experiment for triazole derivative 1b.
Figure 1. The ROESY experiment for triazole derivative 1b.
Molecules 24 04388 g001
Table
Table 1. The 1H NMR chemical shifts and proton-proton correlations (ROESY and COSY experiments) for compound 1b.
Table 1. The 1H NMR chemical shifts and proton-proton correlations (ROESY and COSY experiments) for compound 1b.
1H NMRROESYCOSY
5.22 CH2NTh5.22/7.465.22/7.61
5.49 CH2NTr5.49/7.23/7.615.49/7.23/7.61
6.76 H36.76/7.23/7.926.76/7.23/7.92
6.93 H86.93/7.466.93/7.46/7.92
7.23 o-HPh, 1H47.23/6.76/7.357.23/6.76/7.35/7.92
7.35 m,p-HPh7.35/7.237.35/7.23
7.46 H97.61/5.227.46/6.93/7.92
7.61 HTr7.61/5.49/7.237.61/5.22
7.92 H7 + H27.92/6.76/6.937.92/6.76/6.93/7.23/7.46
Table
Table 2. Anticancer activities IC50 (μM) of 10-substituted 3,6-diazaphenothiazines (1b–4f) against glioblastoma SNB-19, colorectal carcinoma Caco-2, lung cancer A549, breast cancer MDA-MB231 cells and normal human fibroblasts NHDF.
Table 2. Anticancer activities IC50 (μM) of 10-substituted 3,6-diazaphenothiazines (1b–4f) against glioblastoma SNB-19, colorectal carcinoma Caco-2, lung cancer A549, breast cancer MDA-MB231 cells and normal human fibroblasts NHDF.
NoAnticancer Activity IC50 (μM)
SNB-19Caco-2A549MDA-MB231NHDF
1b69.15+/−3.1419.92+/-2.71>10013.66+/−1.16>100
1c5.72+/−1.448.10+/−0.9229.12+/−2.597.82+/−1.32>100
1d4.66+/−1.160.25+/−0.020.25+/−0.010.51+/−0.09>100
1e9.65+/−1.9979.65+/−4.121.79+/−0.6225.79+/−1.32>100
1f>100>100>10068.68+/−5.12>100
2b41.91+/−3.15>10077.44+/−3.2256.34+/−5.72>100
2c55.23+/−5.7843.61+/−6.5260.23+/−2.779.21+/−3.01>100
2d59.87+/−9.9911.42+/−2.131.82+/−0.714.71+/−0.2242.95+/−5.11
2e10.62+/−1.1134.38+/−2.7263.75+/−2.7812.04+/−2.21>100
2f56.34+/−5.7232.55+/−8.2146.80+/−2.7312.04+/−6.11>100
3b2.04+/−0.210.26+/−0.010.26+/−0.110.77+/−0.1022.66+/−1.32
3c57.92+/−4.9629.87+/−5.2127.23+/−2.1625.66+/−4.1170.61+/−12.21
3d31.31+/−10.9933.07+/−9.1817.91+/−1.114.26+/−0.15>100
3e26.80+/−1.7210.02+/−0.9930.07+/−3.213.50+/−0.3549.47+/−1.11
3f32.58+/−2.7714.54+/−1.220.65+/−0.100.64+/−0.1052.90+/−3.21
4b20.80+/−1.9657.90+/−2.1560.62+/−3.527.87+/−1.11>100
4c6.25+/−0.620.25+/−0.020.25+/−0.011.97+/−0.132.85+/−0.34
4d14.87+/−1.7042.06+/−2.9953.99+/−10.7213.44+/−1.22>100
4e53.62+/−3.7274.28+/−4.7242.69+/−13.7238.77+/−2.12>100
4f44.83+/−13.6267.52+/−11.87>10044.33+/−11.79>100
Cisplatin3.73+/−0.6210.53+/−1.520.60+/−0.113.13+/−0.2463.87+/−1.32
Table
Table 3. The influence of compound 1d on expression of genes encoding H3, TP53, CDKN1A, BCL-2, and BAX in glioblastoma SNB-19, colorectal carcinoma Caco-2, lung cancer A549, and breast cancer MDA-MB231 cells.
Table 3. The influence of compound 1d on expression of genes encoding H3, TP53, CDKN1A, BCL-2, and BAX in glioblastoma SNB-19, colorectal carcinoma Caco-2, lung cancer A549, and breast cancer MDA-MB231 cells.
gene SNB-19Caco-2A549MDA-MB231
Number of mRNA Copies/μg Total RNA
H3control143+/−4111+/−323+/-132+/−1
1d52+/−1145+/−318+/−58+/−6
TP53control198+/−5265+/−2449+/−1756+/−16
1d128+/−24193+/−1654+/−1946+/−20
CDKN1Acontrol 698+/−34266+/−491012+/−143710+/−486
1d308+/−51260+/−21969+/−137 577+/−308
BCL-2control 70604+/−7852673718+/−5299822485+/−4794207802+/−15572
1d17497+/−4607723708+/−21713415631+/−229616495+/−4607
BAXcontrol 995+/−981062+/−1411181+/−132835+/−63
1d220+/−18969+/−264835+/−231221+/−16
BCL-2/BAXcontrol7163419249
1d80743 1880

Share and Cite

MDPI and ACS Style

Morak-Młodawska, B.; Pluta, K.; Latocha, M.; Jeleń, M.; Kuśmierz, D. Design, Synthesis, and Structural Characterization of Novel Diazaphenothiazines with 1,2,3-Triazole Substituents as Promising Antiproliferative Agents. Molecules 2019, 24, 4388. https://doi.org/10.3390/molecules24234388

AMA Style

Morak-Młodawska B, Pluta K, Latocha M, Jeleń M, Kuśmierz D. Design, Synthesis, and Structural Characterization of Novel Diazaphenothiazines with 1,2,3-Triazole Substituents as Promising Antiproliferative Agents. Molecules. 2019; 24(23):4388. https://doi.org/10.3390/molecules24234388

Chicago/Turabian Style

Morak-Młodawska, Beata, Krystian Pluta, Małgorzata Latocha, Małgorzata Jeleń, and Dariusz Kuśmierz. 2019. "Design, Synthesis, and Structural Characterization of Novel Diazaphenothiazines with 1,2,3-Triazole Substituents as Promising Antiproliferative Agents" Molecules 24, no. 23: 4388. https://doi.org/10.3390/molecules24234388

APA Style

Morak-Młodawska, B., Pluta, K., Latocha, M., Jeleń, M., & Kuśmierz, D. (2019). Design, Synthesis, and Structural Characterization of Novel Diazaphenothiazines with 1,2,3-Triazole Substituents as Promising Antiproliferative Agents. Molecules, 24(23), 4388. https://doi.org/10.3390/molecules24234388

Article Metrics

Back to TopTop